Nanobodies against C. difficile TcdA and TcdB reveal unexpected neutralizing epitopes and provide a toolkit for toxin quantitation in vivo
-
Published:2023-10-23
Issue:10
Volume:19
Page:e1011496
-
ISSN:1553-7374
-
Container-title:PLOS Pathogens
-
language:en
-
Short-container-title:PLoS Pathog
Author:
Kordus Shannon L.,
Kroh Heather K.,
Rodríguez Rubén Cano,
Shrem Rebecca A.,
Peritore-Galve F. Christopher,
Shupe John A.,
Wadzinski Brian E.,
Lacy D. Borden,
Spiller Benjamin W.ORCID
Abstract
Clostridioides difficile is a leading cause of antibiotic-associated diarrhea and nosocomial infection in the United States. The symptoms of C. difficile infection (CDI) are associated with the production of two homologous protein toxins, TcdA and TcdB. The toxins are considered bona fide targets for clinical diagnosis as well as the development of novel prevention and therapeutic strategies. While there are extensive studies that document these efforts, there are several gaps in knowledge that could benefit from the creation of new research tools. First, we now appreciate that while TcdA sequences are conserved, TcdB sequences can vary across the span of circulating clinical isolates. An understanding of the TcdA and TcdB epitopes that drive broadly neutralizing antibody responses could advance the effort to identify safe and effective toxin-protein chimeras and fragments for vaccine development. Further, an understanding of TcdA and TcdB concentration changes in vivo can guide research into how host and microbiome-focused interventions affect the virulence potential of C. difficile. We have developed a panel of alpaca-derived nanobodies that bind specific structural and functional domains of TcdA and TcdB. We note that many of the potent neutralizers of TcdA bind epitopes within the delivery domain, a finding that could reflect roles of the delivery domain in receptor binding and/or the conserved role of pore-formation in the delivery of the toxin enzyme domains to the cytosol. In contrast, neutralizing epitopes for TcdB were found in multiple domains. The nanobodies were also used for the creation of sandwich ELISA assays that allow for quantitation of TcdA and/or TcdB in vitro and in the cecal and fecal contents of infected mice. We anticipate these reagents and assays will allow researchers to monitor the dynamics of TcdA and TcdB production over time, and the impact of various experimental interventions on toxin production in vivo.
Funder
National Institutes of Health
U.S. Department of Veterans Affairs
National Instutues of Health
Publisher
Public Library of Science (PLoS)
Subject
Virology,Genetics,Molecular Biology,Immunology,Microbiology,Parasitology
Reference54 articles.
1. Clostridium difficile infection;WK Smits;Nat Rev Dis Primers,2016
2. CDC. Antibiotic Resistance Threats in the United States. Atalanta, GA: U.S. Department of Health and Human Services; 2019.
3. Trends in U.S. Burden of Clostridioides difficile Infection and Outcomes;AY Guh;N Engl J Med,2020
4. The role of toxins in Clostridium difficile infection;R Chandrasekaran;FEMS microbiology reviews,2017
5. Phase 3 CLOVER Trial for Pfizer’s Investigational Clostridioides Difficile Vaccine Indicates Strong Potential Effect in Reducing Duration and Severity of Disease Based on Secondary Endpoints. In: https://www.pfizer.com/news/press-release/press-release-detail/phase-3-clover-trial-pfizers-investigational-clostridioides.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献